Worth reading
56In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
296.3
% (year-on-year change in operating profit)Wording
Conditional
How definitive the wording is.Results for this period
Interim period (second quarter)令和７年６月１日〜令和７年11月30日ConsolidatedJapanese GAAPNet Sales33,602¥ millionYear on year +10.0%Progress 50.3%
Operating profit399¥ millionYear on year +296.3%Progress 35.5%
Ordinary income328¥ millionProgress 34.9%
Net income attributable to owners of the parent111¥ millionProgress 41.7%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share9.75円
Financial position at period-end
Total assets29,956¥ million
of which net assets 6,834 ¥ millionEquity ratio 22.1%vs. prior year-end +1.2pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating-220
Investment-449
Financials-1,666
Net change-2,335
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥2,555 million
Segment revenue
Dispensing Pharmacy Business28,47984.8%+14.2%
Retail Business4,08312.2%-9.3%
Medical Records Storage and Management Business3221.0%+3.6%
Medical mall management business2570.8%+0.1%
Other (outside reportable segments)4591.4%-15.7%
Segment profit
Dispensing Pharmacy Business589+190.5%
Retail Business-21
Medical Records Storage and Management Business43+90.9%
Medical mall management business48-16.9%
Other (outside reportable segments)-92
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥66,795 million (YoY +5.2%)
Operating profit¥1,123 million (YoY +282.2%)
Ordinary income¥941 million (YoY +587.3%)
Net income¥266 million
Annual Dividend Forecast14 yen and sen → 14 yen and sen（0.0%）
Factors Behind Changes in Business Performance
M&Aによる店舗数拡大と新規出店で調剤売上高が増加した。利益面では、調剤薬局事業の利益改善、M&Aでグループ入りした店舗の利益増加、本部業務効率化による販管費率減少が増益要因となった。
Disclosure regarding the going concern assumption
No applicable matters (There are no applicable matters.)
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 companies / Excluded 0 companies / Company name None
Material subsequent events財務上の特約が付された金銭消費貸借契約を締結し、令和７年12月12日に1,500百万円を借り入れた。弁済期限は令和14年11月30日で、無担保。
Impairment loss¥3 million
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥18 million, Subsidy Income ¥22 million, Reversal of allowance for doubtful accounts ¥27 million / Extraordinary loss Loss on Disposal of Fixed Assets ¥3 million, Loss on reduction of fixed assets ¥21 million, Impairment Losses ¥3 million
Depreciation and amortization¥378 million
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingYes (for analysts and institutional investors)
Issued Shares at Period-End12,060,381 Shares
Treasury Shares at Period-End557,856 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 令和７年６月１日〜令和７年11月30日 |
| Net Sales | ¥33,602 million (YoY +10.0%) |
| Operating profit | ¥399 million (YoY +296.3%) |
| Ordinary income | ¥328 million |
| Profit attributable to owners of the parent | ¥111 million |
| Net income per share | 9.75円 |
| Equity ratio | End of the current fiscal period 22.1 / End of previous period 20.9 |
| Total assets | ¥29,956 million |
| Net assets | ¥6,834 million |
| Cash flows from operating activities | ¥-220 million |
| Cash flows from investing activities | ¥-449 million |
| Cash flows from financing activities | ¥-1,666 million |
| Cash and cash equivalents at end of period | ¥2,555 million |
| Full-year earnings forecast | Net Sales ¥66,795 million (YoY +5.2%) / Operating profit ¥1,123 million (YoY +282.2%) / Ordinary income ¥941 million (YoY +587.3%) / Net income ¥266 million |
| Annual Dividend Forecast | 14 yen and sen → 14 yen and sen（0.0%） |
| Segment revenue | Dispensing Pharmacy Business ¥28,479 million (YoY +14.2%) / Retail Business ¥4,083 million (YoY -9.3%) / Medical Records Storage and Management Business ¥322 million (YoY +3.6%) / Medical mall management business ¥257 million (YoY +0.1%) / Other (outside reportable segments) ¥459 million (YoY -15.7%) |
| Segment profit | Dispensing Pharmacy Business ¥589 million (YoY +190.5%) / Retail Business ¥-21 million / Medical Records Storage and Management Business ¥43 million (YoY +90.9%) / Medical mall management business ¥48 million (YoY -16.9%) / Other (outside reportable segments) ¥-92 million |
| Depreciation and amortization | ¥378 million |
| Impairment loss | ¥3 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥18 million, Subsidy Income ¥22 million, Reversal of allowance for doubtful accounts ¥27 million / Extraordinary loss Loss on Disposal of Fixed Assets ¥3 million, Loss on reduction of fixed assets ¥21 million, Impairment Losses ¥3 million |
| Disclosure regarding the going concern assumption | No applicable matters (There are no applicable matters.) |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name None |
| Material subsequent events | 財務上の特約が付された金銭消費貸借契約を締結し、令和７年12月12日に1,500百万円を借り入れた。弁済期限は令和14年11月30日で、無担保。 |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Yes (for analysts and institutional investors) |
| Issued Shares at Period-End | 12,060,381 Shares |
| Treasury Shares at Period-End | 557,856 Shares |
| Factors Behind Changes in Business Performance | M&Aによる店舗数拡大と新規出店で調剤売上高が増加した。利益面では、調剤薬局事業の利益改善、M&Aでグループ入りした店舗の利益増加、本部業務効率化による販管費率減少が増益要因となった。 |
Items this document does not state (6)
Operating MarginRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.調剤薬局事業における前連結会計年度のM&Aによる店舗数拡大で調剤売上高が増加した。利益面では、調剤薬局事業の利益改善、M&Aでグループ入りした店舗の利益増加、本部業務効率化による販管費率の減少が寄与した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.